Clinical Trial

Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML

Study acronym: VHA
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated April 7, 2023 (before its estimated March 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the efficacy and safety of venetoclax combined with homoharringtonine and cytarabine in the treatment of newly diagnosed acute myeloid leukemia.
Trial Details
NCT Number NCT05805098
Lead Sponsor The First Affiliated Hospital of Soochow University
Conditions Acute Myeloid Leukemia
Enrollment 60 participants
Start Date 2023-03-01
Primary Completion 2025-03-01 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2023-04-07